Division of Cardiovascular Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
JACC Heart Fail. 2022 Jun;10(6):397-403. doi: 10.1016/j.jchf.2022.04.003.
As utilization of veno-arterial extracorporeal life support (VA-ECLS) in treatment of cardiogenic shock (CS) continues to expand, clinical variables that guide clinicians in early recognition of myocardial recovery and therefore, improved survival, after VA-ECLS are critical. There remains a paucity of literature on early postinitiation blood pressure measurements that predict improved outcomes.
The objective of this study is to help identify early blood pressure variables associated with improved outcomes in VA-ECLS.
The authors queried the ELSO (Extracorporeal Life Support Organization) registry for cardiogenic shock patients treated with VA-ECLS or venovenous arterial ECLS between 2009 and 2020. Their inclusion criteria included treatment with VA-ECLS or venovenous arterial ECLS; absence of pre-existing durable right, left, or biventricular assist devices; no pre-ECLS cardiac arrest; and no surgical or percutaneously placed left ventricular venting devices during their ECLS runs. Their primary outcome of interest was the survival to discharge during index hospitalization.
A total of 2,400 CS patients met the authors' inclusion criteria and had complete documentation of blood pressures. Actual mortality during index hospitalization in their cohort was 49.5% and survivors were younger and more likely to be Caucasian, intubated for >30 hours pre-ECLS initiation, and had a favorable baseline SAVE (Survival After Veno-arterial ECMO) score (P < 0.05 for all). Multivariable regression analyses adjusting for SAVE score, age, ECLS flow at 4 hours, and race showed that every 10-mm Hg increase in baseline systolic blood pressure (HR: 0.92 [95% CI: 0.89-0.95]; P < 0.001), and baseline pulse pressure (HR: 0.88 [95% CI: 0.84-0.91]; P < 0.001) at 24 hours was associated with a statistically significant reduction in mortality.
Early (within 24 hours) improvements in pulse pressure and systolic blood pressure from baseline are associated with improved survival to discharge among CS patients treated with VA-ECLS.
随着静脉-动脉体外膜肺氧合(VA-ECLS)在治疗心源性休克(CS)中的应用不断扩大,指导临床医生早期识别心肌恢复的临床变量对于改善预后至关重要。目前关于启动 VA-ECLS 后早期血压测量预测改善预后的文献仍然很少。
本研究旨在帮助确定与 VA-ECLS 治疗 CS 患者预后改善相关的早期血压变量。
作者查询了 ELSO(体外生命支持组织)登记处 2009 年至 2020 年间接受 VA-ECLS 或静脉-动脉 ECLS 治疗的 CS 患者。他们的纳入标准包括接受 VA-ECLS 或静脉-动脉 ECLS 治疗;无预先存在的持久右、左或双心室辅助装置;ECLS 前无心脏骤停;在 ECLS 运行期间无手术或经皮左心室通风装置。他们的主要研究结果是住院期间的生存出院率。
共有 2400 名 CS 患者符合作者的纳入标准,并完整记录了血压数据。他们队列中的实际住院期间死亡率为 49.5%,存活者年龄更小,更可能是白人,ECLS 启动前插管时间超过 30 小时,基线 SAVE(静脉-动脉 ECMO 后生存)评分较好(所有 P 值均<0.05)。调整 SAVE 评分、年龄、4 小时 ECLS 流量和种族后多变量回归分析显示,基线收缩压每增加 10mmHg(HR:0.92[95%CI:0.89-0.95];P<0.001)和基线脉压(HR:0.88[95%CI:0.84-0.91];P<0.001)与死亡率的降低具有统计学意义。
VA-ECLS 治疗 CS 患者的早期(24 小时内)脉压和收缩压从基线的改善与出院时的生存率提高相关。